Literature DB >> 28585289

Effects of weak/non-complement-binding HLA antibodies on C1q-binding.

G Hönger1,2, P Amico3, M-L Arnold4, B M Spriewald5, S Schaub1,2,3.   

Abstract

It is unknown under what conditions and to what extent weak/non-complement (C)-binding IgG subclasses (IgG2/IgG4) can block C1q-binding triggered by C-binding IgG subclasses (IgG1/IgG3). Therefore, we investigated in vitro C1q-binding induced by IgG subclass mixtures targeting the same HLA epitope. Various mixtures of HLA class II specific monoclonal antibodies of different IgG subclasses but identical V-region were incubated with HLA DRB1*07:01 beads and monitored for C1q-binding. The lowest concentration to achieve maximum C1q-binding was measured for IgG3, followed by IgG1, while IgG2 and IgG4 did not show appreciable C1q-binding. C1q-binding occurred only after a critical amount of IgG1/3 has bound and sharply increased thereafter. When both, C-binding and weak/non-C-binding IgG subclasses were mixed, C1q-binding was diminished proportionally to the fraction of IgG2/4. A 2- to 4-fold excess of IgG2/4 inhibited C1q-binding by 50%. Very high levels (10-fold excess) almost completely abrogated C1q-binding even in the presence of significant IgG1/3 levels that would usually lead to strong C1q-binding. In sensitized renal allograft recipients, IgG subclass constellations with ≥ 2-fold excess of IgG2/4 over IgG1/3 were present in 23/66 patients (34.8%) and overall revealed slightly decreased C1q signals. However, spiking of patient sera with IgG2 targeting a different epitope than the patient's IgG1/3 synergistically increased C1q-binding. In conclusion, if targeting the same epitope, an excess of IgG2/4 is repressing the extent of IgG1/3 triggered C1q-binding in vitro. Such IgG subclass constellations are present in about a third of sensitized patients and their net effect on C1q-binding is slightly inhibitory.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990in vitrozzm321990; C1q-binding; HLA antibody; IgG subclass; allo-reactivity

Mesh:

Substances:

Year:  2017        PMID: 28585289     DOI: 10.1111/tan.13062

Source DB:  PubMed          Journal:  HLA        ISSN: 2059-2302            Impact factor:   4.513


  4 in total

1.  Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Authors:  Antoine Bouquegneau; Charlotte Loheac; Olivier Aubert; Yassine Bouatou; Denis Viglietti; Jean-Philippe Empana; Camilo Ulloa; Mohammad Hassan Murad; Christophe Legendre; Denis Glotz; Annette M Jackson; Adriana Zeevi; Stephan Schaub; Jean-Luc Taupin; Elaine F Reed; John J Friedewald; Dolly B Tyan; Caner Süsal; Ron Shapiro; E Steve Woodle; Luis G Hidalgo; Jacqueline O'Leary; Robert A Montgomery; Jon Kobashigawa; Xavier Jouven; Patricia Jabre; Carmen Lefaucheur; Alexandre Loupy
Journal:  PLoS Med       Date:  2018-05-25       Impact factor: 11.069

2.  Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies.

Authors:  Cynthia S M Kramer; Marry E I Franke-van Dijk; Ashley J Priddey; Tamás Pongrácz; Elena Gnudi; Helena Car; Gonca E Karahan; Els van Beelen; Chalana C C Zilvold-van den Oever; Hendrik J Rademaker; Noortje de Haan; Manfred Wuhrer; Vasilis Kosmoliaptsis; Paul W H I Parren; Arend Mulder; Dave L Roelen; Frans H J Claas; Sebastiaan Heidt
Journal:  HLA       Date:  2019-08-25       Impact factor: 4.513

Review 3.  Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report.

Authors:  Anat R Tambur; Patricia Campbell; Anita S Chong; Sandy Feng; Mandy L Ford; Howard Gebel; Ronald G Gill; Garnett Kelsoe; Vasilis Kosmoliaptsis; Roslyn B Mannon; Michael Mengel; Elaine F Reed; Nicole M Valenzuela; Chris Wiebe; I Esme Dijke; Harold C Sullivan; Peter Nickerson
Journal:  Am J Transplant       Date:  2020-05-27       Impact factor: 8.086

4.  Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR.

Authors:  Cynthia S M Kramer; Marry E I Franke-van Dijk; Kim H Bakker; Merve Uyar-Mercankaya; Gonca E Karahan; Dave L Roelen; Frans H J Claas; Sebastiaan Heidt
Journal:  Am J Transplant       Date:  2020-05-15       Impact factor: 8.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.